204 related articles for article (PubMed ID: 21867560)
1. Advances in the treatment of chronic myeloid leukemia.
Eiring AM; Khorashad JS; Morley K; Deininger MW
BMC Med; 2011 Aug; 9():99. PubMed ID: 21867560
[TBL] [Abstract][Full Text] [Related]
2. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Erba HP; Pham DC; Zaiden R; Vu H; Tai S
Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
[TBL] [Abstract][Full Text] [Related]
4. Targeted drugs in chronic myeloid leukemia.
Gora-Tybor J; Robak T
Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
[TBL] [Abstract][Full Text] [Related]
5. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
DeAngelo DJ; Attar EC
Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
7. [Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with
Lai HR; Wu QM; Yang YZ; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1579-1583. PubMed ID: 37846720
[No Abstract] [Full Text] [Related]
8. New strategies in controlling drug resistance in chronic myeloid leukemia.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
[TBL] [Abstract][Full Text] [Related]
9. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
[TBL] [Abstract][Full Text] [Related]
10. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
O'Hare T; Deininger MW; Eide CA; Clackson T; Druker BJ
Clin Cancer Res; 2011 Jan; 17(2):212-21. PubMed ID: 21098337
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL; Keam SJ
Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
[TBL] [Abstract][Full Text] [Related]
12. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jabbour E; Lipton JH
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
[TBL] [Abstract][Full Text] [Related]
13. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Kujawski L; Talpaz M
Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Jarkowski A; Sweeney RP
Pharmacotherapy; 2008 Nov; 28(11):1374-82. PubMed ID: 18956997
[TBL] [Abstract][Full Text] [Related]
15. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
16. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
Crit Rev Oncol Hematol; 2012 May; 82(2):159-70. PubMed ID: 21565522
[TBL] [Abstract][Full Text] [Related]
17. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
19. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies in chronic myeloid leukemia.
Gora-Tybor J
Curr Cancer Drug Targets; 2012 Jun; 12(5):458-70. PubMed ID: 22483154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]